Article
Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer.
Nature communications - 10 Oct 2023
Macaya Irati, Roman Marta, Welch Connor, Entrialgo-Cadierno Rodrigo, Salmon Marina, Santos Alba, Feliu Iker, Kovalski Joanna, Lopez Ines, Rodriguez-Remirez Maria, Palomino-Echeverria Sara, Lonfgren Shane M, Ferrero Macarena, Calabuig Silvia, Ludwig Iziar A, Lara-Astiaso David, Jantus-Lewintre Eloisa, Guruceaga Elizabeth, Narayanan Shruthi, Ponz-Sarvise Mariano, Pineda-Lucena Antonio, Lecanda Fernando, Ruggero Davide, Khatri Purvesh, Santamaria Enrique, Fernandez-Irigoyen Joaquin, Ferrer Irene, Paz-Ares Luis, Drosten Matthias, Barbacid Mariano, Gil-Bazo Ignacio, Vicent Silve
Abstract excerpt
Drug combinations are key to circumvent resistance mechanisms compromising response to single anti-cancer targeted therapies. The implementation of combinatorial approaches involving MEK1/2 or KRASG12C inhibitors in the context of KRAS-mutated lung cancers focuses fundamentally on targeting KRAS proximal activators or effectors. However, the antitumor effect is highly determined by compensatory mechanisms arising...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.